ArticleFrontiers in oncology2026
Case Report: Anlotinib for advanced chordoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoma is a rare tumor with low to moderate malignancy. It is typically treated with surgical resection in the early stages. However, due to the slow growth and locally invasive biological characteristics of chordoma, patients are often diagnosed at an advanced stage, rendering them ineligible for surgery. This case report describes a 71-year-old male patient who experienced notable symptom relief after receiving single-agent anlotinib treatment for advanced thoracic chordoma. According to the World Health Organization (WHO) criteria for solid tumors, imaging examinations indicated that the patient achieved a partial response (PR). These findings suggest that anlotinib has potential therapeutic value in the treatment of chordoma, primarily in managing symptoms and tumor progression. In this report, we retrospectively analyzed the patient's case data and discussed it in conjunction with relevant literature to provide new therapeutic strategies for clinicians facing similar patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.